These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30860163)

  • 1. Aggressive erosive lichen planus associated with hepatitis C responding to sofosbuvir/ledipasvir treatment.
    Morgado-Carrasco D; Combalia A; Fustà-Novell X; Mascaró JM; Iranzo P
    Indian J Dermatol Venereol Leprol; 2019; 85(3):326-329. PubMed ID: 30860163
    [No Abstract]   [Full Text] [Related]  

  • 2. New-onset cutaneous lichen planus following therapy for hepatitis C with ledipasvir-sofosbuvir.
    Scott GD; Rieger KE
    J Cutan Pathol; 2016 Apr; 43(4):408-9. PubMed ID: 26816004
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety of pembrolizumab while commencing treatment for hepatitis C with Harvoni (ledipasvir and sofosbuvir).
    Menon LL; Chin B; Khattak MA
    Intern Med J; 2018 Dec; 48(12):1542-1543. PubMed ID: 30517998
    [No Abstract]   [Full Text] [Related]  

  • 4. Classical Kaposi's sarcoma concurrent with ledipasvir-sofosbuvir therapy for hepatitis C infection.
    Latini A; Orsini D; Ambrifi M; Colafigli M; Zaccarelli M; Cristaudo A
    G Ital Dermatol Venereol; 2019 Oct; 154(5):593-594. PubMed ID: 29192474
    [No Abstract]   [Full Text] [Related]  

  • 5. Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children.
    Rizza SA; Nehra V; Temesgen Z
    Drugs Today (Barc); 2017 Aug; 53(8):447-451. PubMed ID: 29119149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):111-2. PubMed ID: 25372848
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of Chronic Hepatitis C Virus Infection With Crushed Ledipasvir/Sofosbuvir Administered via a Percutaneous Endoscopic Gastrostomy Tube.
    Jindracek L; Stark J
    J Pharm Pract; 2018 Oct; 31(5):522-524. PubMed ID: 28925327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: Highly effective in a predominantly black male patient population.
    Tang L; Parker A; Flores Y; Dellario M; Dickson C; Amoroso A; Kottilil S; Wilson E
    J Viral Hepat; 2018 Feb; 25(2):205-208. PubMed ID: 28984059
    [No Abstract]   [Full Text] [Related]  

  • 9. Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection.
    Asahina Y; Itoh Y; Ueno Y; Matsuzaki Y; Takikawa Y; Yatsuhashi H; Genda T; Ikeda F; Matsuda T; Dvory-Sobol H; Jiang D; Massetto B; Osinusi AO; Brainard DM; McHutchison JG; Kawada N; Enomoto N
    Liver Int; 2018 Sep; 38(9):1552-1561. PubMed ID: 29297980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of chronic hepatitis C in a kidney transplant patient with only 2 weeks of direct-acting antiviral therapy.
    de Sá Guimarães Cerqueira S; Mesquita MD; Castro RA; Carrola P; Morgado TMPR; Marques P
    Nefrologia (Engl Ed); 2018; 38(6):671-672. PubMed ID: 29871768
    [No Abstract]   [Full Text] [Related]  

  • 11. Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans.
    Britnell SR; Willets AE; Vanderman AJ; Woodard CL; Britt RB
    Pharmacotherapy; 2016 Nov; 36(11):1173-1179. PubMed ID: 27716978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study).
    Boerekamps A; Vanwolleghem T; van der Valk M; van den Berk GE; van Kasteren M; Posthouwer D; Dofferhoff ASM; van Hoek B; Ramsoekh D; Koopsen J; Schinkel J; Florence E; Arends JE; Rijnders BJ
    J Hepatol; 2019 Mar; 70(3):554-557. PubMed ID: 30527953
    [No Abstract]   [Full Text] [Related]  

  • 13. Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.
    Smith MA; Chan J; Mohammad RA
    Ann Pharmacother; 2015 Mar; 49(3):343-50. PubMed ID: 25515863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sofosbuvir/ledipasvir is also effective in routine general practice].
    Warpakowski A
    MMW Fortschr Med; 2016 Apr; 158 Spec No 1():65. PubMed ID: 27090681
    [No Abstract]   [Full Text] [Related]  

  • 15. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
    Zeng QL; Xu GH; Zhang JY; Li W; Zhang DW; Li ZQ; Liang HX; Li CX; Yu ZJ
    J Hepatol; 2017 Jun; 66(6):1123-1129. PubMed ID: 28189754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus.
    Lim YS; Ahn SH; Lee KS; Paik SW; Lee YJ; Jeong SH; Kim JH; Yoon SK; Yim HJ; Tak WY; Han SY; Yang JC; Mo H; Garrison KL; Gao B; Knox SJ; Pang PS; Kim YJ; Byun KS; Kim YS; Heo J; Han KH
    Hepatol Int; 2016 Nov; 10(6):947-955. PubMed ID: 27198664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis.
    Essa M; Sabry A; Abdelsameea E; Tharwa ES; Salama M
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):53-58. PubMed ID: 30247174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of de novo hepatitis C virus-related fibrosing cholestatic hepatitis after orthotopic heart transplantation by ledipasvir and sofosbuvir.
    Liu CH; Chen YS; Wang SS; Kao JH
    J Formos Med Assoc; 2017 May; 116(5):407-409. PubMed ID: 28089092
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatitis C virus genotype 1 NS5A variants in Japanese patients.
    Vilchez RA
    Lancet Infect Dis; 2015 Dec; 15(12):1378. PubMed ID: 26607122
    [No Abstract]   [Full Text] [Related]  

  • 20. A pill a day keeps HCV away.
    Gentile I; Borgia G
    Lancet Infect Dis; 2015 Jun; 15(6):616-7. PubMed ID: 25863561
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.